RxDoctor Payments Data

Sarah Lopez, DO

Internal Medicine · San Antonio, TXNPI 1962935635

Payments from drug & device makers

$2,081in general payments, 2019–2025

Across 25 payments — averaging $83.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$480
  • Amgen$366
  • AbbVie$349
  • Johnson & Johnson$312
  • Bayer$125
  • Amarin Pharma, Inc.$116
  • plus $334 from 5 others

What the payments were for

  • Food & beverage$2,081100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC6$480
Amgen5$366
AbbVie3$349
Johnson & Johnson3$312
Bayer1$125
Amarin Pharma, Inc.1$116
Abbott1$108
Merck1$89
AstraZeneca1$77
Biogen2$31
Pfizer1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,081 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$23,588
Medicare patients
106
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$48,681
JardianceEmpagliflozin42$42,469
MounjaroTirzepatide36$38,439
JanuviaSitagliptin Phosphate13$20,660
VascepaIcosapent Ethyl23$17,600
XareltoRivaroxaban16$14,662
Aripiprazole17$5,565
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,325
Lidocaine21$1,880
Albuterol Sulfate HfaAlbuterol Sulfate57$1,658
Levothyroxine Sodium140$1,313
Wixela InhubFluticasone Propion/Salmeterol12$1,264
Atorvastatin Calcium234$1,198
Ezetimibe51$954
Nifedipine ErNifedipine28$944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$480$38,43936 claims
MerckJanuvia$89$20,66013 claims
Johnson & JohnsonXarelto$312$14,66216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →